» Articles » PMID: 21304480

Epidemiology of Alzheimer Disease

Overview
Journal Nat Rev Neurol
Specialty Neurology
Date 2011 Feb 10
PMID 21304480
Citations 602
Authors
Affiliations
Soon will be listed here.
Abstract

The global prevalence of dementia is estimated to be as high as 24 million, and is predicted to double every 20 years through to 2040, leading to a costly burden of disease. Alzheimer disease (AD) is the leading cause of dementia and is characterized by a progressive decline in cognitive function, which typically begins with deterioration in memory. Before death, individuals with this disorder have usually become dependent on caregivers. The neuropathological hallmarks of the AD brain are diffuse and neuritic extracellular amyloid plaques-which are frequently surrounded by dystrophic neurites-and intracellular neurofibrillary tangles. These hallmark pathologies are often accompanied by the presence of reactive microgliosis and the loss of neurons, white matter and synapses. The etiological mechanisms underlying the neuropathological changes in AD remain unclear, but are probably affected by both environmental and genetic factors. Here, we provide an overview of the criteria used in the diagnosis of AD, highlighting how this disease is related to, but distinct from, normal aging. We also summarize current information relating to AD prevalence, incidence and risk factors, and review the biomarkers that may be used for risk assessment and in diagnosis.

Citing Articles

From Molecules to Mind: The Critical Role of Chitosan, Collagen, Alginate, and Other Biopolymers in Neuroprotection and Neurodegeneration.

Kruczkowska W, Galeziewska J, Grabowska K, Gromek P, Czajkowska K, Rybicki M Molecules. 2025; 30(5).

PMID: 40076240 PMC: 11901451. DOI: 10.3390/molecules30051017.


Brain interleukins and Alzheimer's disease.

Abdelhamed H, Hassan A, Sakraan A, Al-Deeb R, Mousa D, Aboul Ezz H Metab Brain Dis. 2025; 40(2):116.

PMID: 39891777 PMC: 11787210. DOI: 10.1007/s11011-025-01538-5.


Perceptions and practices of imaging personnel and physicians regarding the use of brain MRI for dementia diagnosis in Uganda.

Nassanga R, Nakasujja N, Kaddumukasa M, Jones S, Sajatovic M, Kawooya M PLoS One. 2025; 20(1):e0305788.

PMID: 39823447 PMC: 11741567. DOI: 10.1371/journal.pone.0305788.


Effects of aerobic exercise on cognitive function and quality of life in patients with Alzheimer's disease: a systematic review and meta-analysis.

Yang L, Yuan Z, Peng C BMJ Open. 2025; 15(1):e090623.

PMID: 39800395 PMC: 11752035. DOI: 10.1136/bmjopen-2024-090623.


Pharmacogenomics for neurodegenerative disorders - a focused review.

Ahmad S, Zeyaullah M, Khan M, AlShahrani A, Altijani A, Ali H Front Pharmacol. 2025; 15:1478964.

PMID: 39759457 PMC: 11695131. DOI: 10.3389/fphar.2024.1478964.


References
1.
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

2.
Michikawa M . Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. J Neurosci Res. 2003; 72(2):141-6. DOI: 10.1002/jnr.10585. View

3.
Rovio S, Kareholt I, Helkala E, Viitanen M, Winblad B, Tuomilehto J . Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005; 4(11):705-11. DOI: 10.1016/S1474-4422(05)70198-8. View

4.
Hartman R, Laurer H, Longhi L, Bales K, Paul S, McIntosh T . Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci. 2002; 22(23):10083-7. PMC: 6758744. View

5.
Beecham G, Martin E, Li Y, Slifer M, Gilbert J, Haines J . Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009; 84(1):35-43. PMC: 2668056. DOI: 10.1016/j.ajhg.2008.12.008. View